Skip to main content

Harvard Apparatus Regenerative Technology, Inc.

For the period ended Dec 31, 2024. Filed Mar 31, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 31, 2025

HRGNStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Table of Contents

INDEX

Page
PART I
Item 1.Business1
Item 1A.Risk Factors22
Item 1B.Unresolved Staff Comments40
Item 1C.Cybersecurity40
Item 2.Properties40
Item 3.Legal Proceedings40
Item 4.Mine Safety Disclosures40
PART II
Item 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities41
Item 6.Selected Financial Data41
Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations42
Item 7A.Quantitative and Qualitative Disclosures About Market Risk47
Item 8.Financial Statements and Supplementary Data47
Item 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure47
Item 9A.Controls and Procedures47
Item 9B.Other Information48
Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections48
PART III
Item 10.Directors, Executive Officers and Corporate Governance49
Item 11.Executive Compensation49
Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters49
Item 13.Certain Relationships and Related Transactions, and Director Independence49
Item 14.Principal Accounting Fees and Services49
PART IV
Item 15.Exhibits, Financial Statement Schedules49
Index to Consolidated Financial StatementsF-1
Signatures53

i

Forward-Looking Statements

This Annual Report on Form 10-K contains statements that are not statements of historical fact and are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the "Exchange Act"), each as amended. The forward-looking statements are principally, but not exclusively, contained in“Item 1: Business”* and*“Item 7: Management’s Discussion and Analysis of Financial Condition and Results of Operations.”* These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about management*’s confidence or expectations and our plans, objectives, expectations and intentions that are not historical facts. In some cases, you can identify forward-looking statements by terms such as“may,”* “will,” “should,” “could,” “would,” “seek,” “expect,” “plans,” “aim,” “anticipates,” “believes,” “estimates,” “project,” “predict,” “intend,” “think,” “continue,” “potential,” “likely,” “permit,” “objectives,” “optimistic,” “new,” “goal,” “target,” “strategy” and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in detail under the heading*“Item 1A. Risk Factors”* beginning on page 22 of this Annual Report on Form 10-K. You should carefully review all of these factors, as well as other risks described in our public filings, and you should be aware that there may be other factors, including factors of which we are not currently aware, that could cause these differences. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this Annual Report on Form 10-K. We may not update these forward-looking statements, even though our situation may change in the future, unless we have obligations under the federal securities laws to update and disclose material developments related to previously disclosed information. Harvard Apparatus Regenerative Technology, Inc. is referred to herein as*“we,”* “our,” “us,” and*“the Company.”

ii

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.